EP0674522A1 - Mucilage de graines de lin - Google Patents

Mucilage de graines de lin

Info

Publication number
EP0674522A1
EP0674522A1 EP93904227A EP93904227A EP0674522A1 EP 0674522 A1 EP0674522 A1 EP 0674522A1 EP 93904227 A EP93904227 A EP 93904227A EP 93904227 A EP93904227 A EP 93904227A EP 0674522 A1 EP0674522 A1 EP 0674522A1
Authority
EP
European Patent Office
Prior art keywords
mucilage
linseed
linseed mucilage
composition
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93904227A
Other languages
German (de)
English (en)
Inventor
John Edward Smithkline Beecham O'mullane
Ian Peter Smithkline Beecham Hayter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0674522A1 publication Critical patent/EP0674522A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • This invention relates to compositions of matter comprising Unseed mucilage and purified forms thereof, processes for their preparation and cosmetic and therapeutic applications thereof.
  • linseed mucilage is a viscous liquid obtained by an aqueous extraction of the seeds of the Unseed plant. Linseed mucilage acts as a bulking agent and is used in the treatment of constipation. Linseed mucilage is recommended as a herbal remedy for the treatment of gastric disorders and for improving the general health of the digestive tract.
  • sucralfate sulphated sucrose and aluminium hydroxide
  • bioadhesive materials have utility as muco-adherents and may be used by themselves or in conjunction with one or more therapeutically active materials.
  • linseed mucilage has bioadhesive properties which confer practical utility when the material is appUed to the skin and mucous membrances of the body, both in isolation and in combination with other active treating substances. Tests have shown a positive mucus- mucilage interaction.
  • linseed mucilage As a non-irritant, natural product, linseed mucilage has distinct advantages when applied to the body for cosmetic and/or therapeutic purposes.
  • composition of matter comprising Unseed mucilage for the manufacture of a medicament for topical application to the skin and/or mucous membranes of the human or animal body.
  • the invention provides the use of a composition of matter comprising linseed mucilage as a cosmetic preparation for topical application to the skin and/or mucous membranes of the human body.
  • a composition of matter comprising linseed mucilage as a cosmetic preparation for topical application to the skin and/or mucous membranes of the human body.
  • Amo gst the many and varied uses of linseed mucilage as a mucosal or mucous-adherent are included its use as an artificial mucus and/or lubricant for appUcation to the skin surface, the occular, nasal, oral, vaginal and anal cavities; its use as a mucoadherent in the gastrointestinal tract; and its use as a cytoprotective agent.
  • Unseed mucilage as an artificial mucus and/c.. lubricant
  • Examples of the use of Unseed mucilage as an artificial mucus and/c.. lubricant include its use in the treatment of dry-eye, xerostomia and radiotherapy induced secretory cell disorders, for example where the secretory cells in the saUvary gland are destroyed.
  • linseed mucilage As a cytoprotective agent, linseed mucilage has been shown to compare favourably with other muco-adherents, for example sucralfate, in preventing lesions.
  • topical appUcation is not limited to appUcation to the skin and/or exposed mucous surfaces of the body but rather includes any such surface, whether internal or external.
  • composition of matter comprising linseed mucilage in combination with an active treating substance has utiUty as a delivery system for effecting locaUsed and/or controlled release of the active treating substance.
  • Such combinations for example when administered orally, have moreover a cytoprotective effect and are useful in preventing or mitigating damage induced by said active treating substances.
  • the present invention provides a composition of matter comprising linseed mucilage in combination with an active treating substance.
  • a method of controlled release treatment also constitutes an aspect of the invention.
  • the term active treating substance includes medicaments, cosmetic substances and nutritional agents.
  • Cosmetic substances as referred to herein include sun-screening agents, skin treatments such as skin softeners and anti-acne agents, perfumes and the like.
  • Nutritional substances as referred to herein include vitamins and minerals.
  • medicament as used herein refers to any therapeutic substance, suitably any therapeutic substance that is effective via application to the skin or any of the mucous sites hereinbefore described.
  • combination of an active therapeutic substance with linseed mucilage can confer not only controUed release cf the substance but, in addition, depending on the nature and purpose of the substance, retention of the substance at the target site promoting, inter alia, a localised effect at the target site, or, for substances which are absorbed either transdermally through the skin surface or via mucous surfaces, an effective means for deUvering the active therapeutic substance to the systemic system.
  • An active treating substance as used in compositions of the present invention may be used singly or in combination with one or more other active treating substances.
  • An active treating substance more particularly an active treating substance which is a medicament, will be present in the composition in an amount that is sufficient to prevent, cure and/or alleviate the condition requiring treatment. Such an amount is referred to hereinafter as an effective amount of the active treating substance.
  • the effective amount of a given active treating substance is dependent on the substance, for example its physico-chemical properties such as molecular weight and charge, the condition requiring treatment and the manner of administration. Such amounts may be determined by methods known in the art of biophysical chemistry.
  • Linseed mucilage for use in the present invention may be in the form of a viscous liquid, the viscosity of which may be selected to suit for example mode and/or site of administration.
  • liquid Unseed mucilage preparations may be administered as a mouth rinse, wash or spray for retention in the oral cavity or as a liquid presentation, eg. a syrup for swallowing.
  • linseed mucilage may be in a dried form for reconstitution with water prior to use, or for reconstitution on contact with body fluids at a mucous surface of the body.
  • Linseed mucilage and purified forms thereof may for example be dried to form a powder or alternatively, cast as a thin film which on rehydration adheres to the surface of the skin or mucuous membrane to which it is appUed.
  • Linseed mucilage for use in the invention may be incorporated in a range of product presentations for oral deUvery, including pastes and gelled products, such as gums, for example a chewing gum, and lozenge presentations. Presentations for oral deUvery may be formulated for retention in the mouth, for example to be sucked, chewed or appUed to the teeth or gums, or as presentations intended for swallowing. Where an active treating substance is combined with Unseed mucilage and is intended to treat or prevent disorders associated with the oral cavity, the product is suitably formulated for retention in the mouth. Alternatively, where the active treating substance is intended to treat or prevent disorders requiring absorption of the substance from the gastrointestinal tract, the product may be formulated either for release of the active substance in the mouth or preferably a swallow product.
  • Processes for preparing raw linseed mucilage, dried forms thereof and gels, for example gum, lozenge and thin film formulations are a feature of the present invention.
  • Raw linseed mucilage may for example be obtained as a viscous, pseudoplastic Uquid by boiling Unseed in water, suitably for 2 to 10 minutes, favourably for 3 to 5 minutes, and filtering the product.
  • linseed mucilage having a dry weight of 1.0 to 1.6g per 100ml is obtained -from an extraction of 1 part linseed to 10 parts water under these conditions.
  • the seeds may be cracked prior to processing but use of whole, intact seed is generally preferred.
  • Unseed mucilage may be prepared from separated seed-coats. Percentage dry weight is dependent on a number of variables including for example seed-type and the extraction conditions employed for isolating the mucilage.
  • Unseed mucilage may also be obtained by aqueous extraction over a range of temperatures, for example at room temperature in which case the extraction process may extend over several hours.
  • Mucilage obtained by extraction at or around room temperature generally has a lower percentage dry weight than material obtained by extraction at elevated temperature.
  • the liquid product may be dried using state of the art drying techniques, for example oven-, freeze- and spray-drying techniques, preferably an oven-drying or freeze-drying technique.
  • the native properties of the raw mucilage can be retained by combining it with gelling agents.
  • Such agents would typically be gelatin, natural or synthetic gums.
  • the gelation of the mucilage results in a retention of the native structure and the reconstitution upon dissolution of the gel matrix.
  • the finished product may resemble dosage forms ranging from soft gels to hard lozenges.
  • the rheological properties, for example the pseudoplastic and bioadhesive properties of the raw mucilage are retained on rehydration of dried mucilage, more especially when the dried mucilage is prepared by oven-drying.
  • the raw mucilage is suitably maintained at a temperature of about 60°C.
  • Purified forms of linseed mucilage also form part of the present invention. Dialysis of the mucilage against aqueous solutions removes low molecular weight materials that contribute to the odour and appearance of the mucilage. The dialysis of the mucilage against compositions of choice can be used in order to incorporate other components of formulations.
  • Raw mucilage may be subjected to ultrafiltration, to provide a high molecular weight mucilage fraction.
  • Ultrafiltration for example against a 10,000 molecular weight cut-off membrane against water, may be carried out prior to drying or gelling the raw linseed mucilage.
  • Linseed mucilage which has been subjected to ultrafiltration retains the physical properties of raw mucilage. Morever, when raw mucilage is subjected to ultrafiltration prior to drying, the dried mucilage is obtained as a white, fibrous solid which retains the properties of the raw mucilage when rehydrated.
  • a further purified form a linseed mucilage is obtainable by treating raw linseed mucilage with a low molecular weight, water-soluble alcohol, for example a C .Q alkyl alcohol, such as ethanol or isopropanol. Treatment with the alcohol causes precipitation of a component of the raw mucilage which may be isolated as a fibrous soUd.
  • a low molecular weight, water-soluble alcohol for example a C .Q alkyl alcohol, such as ethanol or isopropanol.
  • the alcohol precipitated material has similar rheological characteristics to the raw mucilage when it is reconstituted into aqueous solutions.
  • the precipitate and he reconstituted material lack the characteristic odour and colour of Unseed mucilage.
  • the reconstituted material is less subject to degradation than the raw material.
  • Alcohol precipitated Unseed mucilage is accordingly a preferred form of mucilage according to the present invention.
  • the alcohol precipitated material in common with raw mucilage, has been shown by chemical characterisation to consist of proteinaceous, saccharide and oil components in covalent or intimate admixture.
  • a typical mucilage preparation may contain up to 15% w/w of protein, up to 98% w/w of saccharides and up to 10% w/w of oils.
  • the composition of a typical alcohol precipitated material is given in Example 4.
  • the present inver ⁇ . also p ⁇ 7 ides linseed mucila and a r, jiod of ireparatio: -hereo herein , ,a rheological proper es, for example the ⁇ scosity of the mucilage in hydrated form, may be controlled to suit a chosen uti ty. It has for example been found that there is a marked difference in rheological behaviour between mucilage preparations, dependent on the amount of Unseed used to prepare the raw mucilage. It has moreover been found that dilution of a concentrated or highly viscous mucilage preparation does not generate a homogenous mucilage preparation having reduced viscosity.
  • the viscosity of such Unseed mucilage preparations is rather controlled by varying the quantity of Unseed present in the mixture of Unseed and water during initial processing.
  • the abiUty to reduce viscosity by dilution is a feature of mucilage preparations of low percentage dry weight which are formed initially as free-flowing viscous liquids. This supports the view that the rheology of linseed mucilage is at least partially determined by a concentration dependent polymeric entanglement.
  • the rheology of linseed mucilage preparations is also dependent on the Unseed variety used to prepare the mucilage. It has been found for example that by subjecting a given amount of different seed types to identical extraction processes, mucilages having a range of viscosities can be obtained.
  • rheology is dependent on the conditions under which the mucilage is extracted from the Unseed. It has been shown that the viscosity of mucilage obtained by aqueous extraction is dependent on temperature, low temperature extraction generally giving rise to less viscous material than extraction at elevated temperature, for example by extraction with boiling water. Differences in rheology may be attributed, at least in part, to the molecular weight of the mucilage extract, extraction at elevated temperature giving rise to a higher proportion of high molecular weight materials.
  • mucilages having viscosities in the range 5 to 5,000 cps and with a percentage dry weight in the range 0.1 to 3.
  • a 1.2% dry weight mucilage will have an initial viscosity in the range 100 to 200cps.
  • the viscosity of linseed mucilage may therefore be selected to accommodate any one of the applications embodied in the present invention; the mucilage may range from a mobile Uquid (eg. 5 to 50 cps, suitably 30 or 35 to 50cps), through a thick but nevertheless pourable Uquid (eg. 50 to 300 cps, suitably 80 to 150cps) to a gellatinous composition (eg. greater than 300cps).
  • a mobile Uquid eg. 5 to 50 cps, suitably 30 or 35 to 50cps
  • a thick but nevertheless pourable Uquid eg. 50 to 300 cps, suitably 80 to 150cps
  • a gellatinous composition eg. greater than 300cps.
  • Unseed mucilage renders it of utility as a viscosity controlling agent in liquid preparations, for example in Uquid preparations for oral consumption.
  • linseed mucilage may be used as a sugar substitute in liquid syrups.
  • Unseed mucilage as a viscosity controlUng agent forms an aspect of the present invention.
  • Unseed mucilage for topical application to the human or animal body is derived from the effect of proteolytic enzymes on the rheological properties of the mucilage. It has been found that the viscosity of a mucilage preparation is reduced as a function of time in the presence of proteolytic enzymes. It will be appreciated that proteolytic degradation can be used to advantage in appUcations according to the invention, for example when Unseed mucilage is used as a drug deUvery system. Particularly suitable appUcations include Unseed mucilage incorporating an active treating substance for delivery to the occular, nasal or vaginal cavities of the body.
  • compositions for use in the present invention may include pharmaceutically or cosmetically acceptable adjuvants for example ex ⁇ pients, lubricants, binders, gelling agents, preservatives, colouring agents and flavouring agents.
  • compositions according to the invention are substantially non-toxic to humans and animals, discounting any toxicity which may be associated with incorporation of an active treating substance.
  • the amount of active treating substance or effective amount of the active treating substance will be an amount that is not expected to confer any unacceptable toxicological effects.
  • Novel linseed mucilage formulations as hereinbefore described form part of the present invention as do their use as novel therapeutic agents, including their use in the treatment of gastric disorders.
  • Linseed mucilage preparations according to the present invention together with data illustrating their rheological properties are described in the foUowing Examples. Linseed mucilage preparations according to the present invention may be prepared from any linseed variety.
  • the mucilage was found to have a dry weight of 1.1 to 1.3g per 100ml.
  • the material was stored at 4°C to avoid bacterial spoilage.
  • Raw linseed mucilage as prepared in Example 1 was placed on a flat stainless steel tray and dried in an oven at 60°C. The resulting yellow/brown film was ground and sieved.
  • Raw linseed mucilage as prepared in Example 1 was frozen in a conventional freezer.
  • the frozen sample was subjected to freeze-drying in a freeze drier.
  • the isolated, freeze-dried mucilage was a fibrous, low- density pale yeUow powder.
  • Raw linseed mucilage as prepared in Example 1 was subjected to ultrafiltration through a 10,000 molecular weight cutoff membrane against water. This process removed the colouration and most of the odour of the raw mucilage, but retained its pseudoplastic properties. The ultrafiltrated mucilage was then freeze-dried to give a dried linseed mucilage as a white fibrous material.
  • Example 4
  • Raw linseed mucilage as prepared in Example 1 was treated with an equal volume of isopropyl alcohol. This treatment precipitated out approximately 80% of the dry weight of the mucilage comprising the protein, saccharide and some residual oil component of the raw mucilage. The initial precipitate was a white, odourless, fibrous material which rehydrated to a mucilage-like material on exposure to air .A typical mucilage preparation would have the following characteristics:
  • Such components may exist as admixtures, intimate mixes or covalent structures such as a glycoprotein or glycoUpid.
  • Nitrogen conversion factor 5.88 (calculated from amino acid data)
  • Viscosity may range from: 5 to 5000 cps
  • the viscosity of a 1% solution fell from 130 cp to 30 cp on standing overnight at room temperature.
  • test material approximately 10ml.
  • distilled water 10ml.
  • Hydrochloric acid 10ml.
  • the suspensions/solutions were monitored for several days whilst being mixed by gentle inversion. The results were as follows:
  • Freeze dried Mucilage - freeze dried powders proved difficult to wet, the material attaining a 'swoUen volume' with time. The time taken to reach this final swollen volume was measureable in days. Hot and boiUng water produced very similar results. The material rehydrated in acid appeared sUghtly less viscous.
  • Spray dried Mucilage The rehydration of the material was examined in both water and O.IM hydrochloric acid.
  • the spray dried material formed a swollen mass in both environments, this slowly dispersed over several days to form a dark brown liquid suspension.
  • the material in O.IM acid appeared to be slightly less viscous than that in water.
  • the addition of boiUng water to the spray dried mucilage appeared to have no effect upon the rehydration.
  • the resuspensions were graded as follows in order of appearance compared to raw mucilage:
  • PAA PolyacryUc acid
  • SDLM Spray-dried Linseed Mucilage
  • Table 1 shows the results obtained for the detachment weights of the investigative materials from mucous, expressed as a percentage of the control.
  • Table 2 shows the corresponding detachment values which were obtained when polyacryUc acid (PAA) and acacia were detached from raw linseed mucilage in place of mucous.
  • PAA polyacryUc acid
  • Table 2 Mean Detachment weight (expressed as a percentage of the control) of Polvacrylic acid (PAA) and acacia from freshly constituted linseed mucilage, employing a contact time between polvmer and mucilage of 5 minutes
  • Isopropanol precipitated linseed mucilage as prepared in Example 4 was suspended in water and treated with gelling agents as described in Example 8. The resulting gels, on treatment with hot water, rehydrated to provide a colourless, odourless mucilage.
  • Drug-mucilage complexes were prepared from linseed mucilage and each of the following compounds: dyclonine, phenylephrine, lignocaine, cimetidine, loperamide, cetyl pyridinium choride (CPC) and chlorhexidine.
  • the complexes were prepared by adding a known quantity of an aqueous solution of the drug to a known volume of linseed mucilage prepared as per Example 1. On mixing mucilage with CPC and chlorhexidine, the complex formed as a fiocculant precipitate which was separated from the aqueous supernatant by centrifugation, washed with water and filtered.
  • the rate of drug release was measured by dialysis of a 1:1 mixture of complex and an aqueous solution of the drug. All experiments were carried out using water as the release medium. An aqueous solution containing the same amount of drug as in the mucilage solutions was simultaneously dialysed with water to act as control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions à base de substances comprenant du mucilage de graines de lin ainsi que des formes purifiées de celui-ci destinées à une utilisation thérapeutique et cosmétique en applications locales sur la peau et/ou sur les muqueuses. Les compositions de mucilage de graines de lin ont des propriétés muco-adhérentes; elles s'utilisent sous forme de mucus ou de lubrifiant et peuvent être associées à des substances de traitement actives.
EP93904227A 1992-02-19 1993-02-18 Mucilage de graines de lin Withdrawn EP0674522A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9203474 1992-02-19
GB929203474A GB9203474D0 (en) 1992-02-19 1992-02-19 Novel composition
PCT/GB1993/000343 WO1993016707A1 (fr) 1992-02-19 1993-02-18 Mucilage de graines de lin

Publications (1)

Publication Number Publication Date
EP0674522A1 true EP0674522A1 (fr) 1995-10-04

Family

ID=10710634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93904227A Withdrawn EP0674522A1 (fr) 1992-02-19 1993-02-18 Mucilage de graines de lin

Country Status (6)

Country Link
EP (1) EP0674522A1 (fr)
JP (1) JPH07504182A (fr)
AU (1) AU3509493A (fr)
CA (1) CA2130350A1 (fr)
GB (1) GB9203474D0 (fr)
WO (1) WO1993016707A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4419818C2 (de) * 1994-06-07 1998-10-22 Lohmann Therapie Syst Lts Wirkstoffträger zur kontrollierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt mit verzögerter Pyloruspassage und Verfahren zur Herstellung desselben
JP2001122733A (ja) * 1999-10-26 2001-05-08 Noevir Co Ltd カタラーゼ産生促進剤、及びこれを含有する皮膚外用剤
KR20010054656A (ko) * 1999-12-07 2001-07-02 유상옥,송운한 아마 추출물과 알파히드록시산을 함유하는 피부보호화장료 조성물
FR2813186B1 (fr) * 2000-08-30 2004-03-12 Mohamed Taleb Reducteur pour permanente
EP1648405A1 (fr) * 2003-05-30 2006-04-26 Isomers Laboratories Inc. Cosmetique comportant comme support un extrait de graine de lin
GB0402539D0 (en) * 2004-02-05 2004-03-10 Sinclair Pharmaceuticals Ltd Xerostomia treatment,composition and method
CA2564632C (fr) * 2004-05-10 2019-06-18 Den Kgl. Veterinaer - Og Landbohojskole Graines de lin permettant de gerer le poids du corps
GB0426850D0 (en) * 2004-12-08 2005-01-12 James Teifion E Medical device
GB0504153D0 (en) * 2005-03-01 2005-04-06 Brooks Sarah Annabelle Lubricating composition
US20060263306A1 (en) * 2005-05-19 2006-11-23 Pauline Pan Compositions having improved substantivity
BRPI0520512A2 (pt) * 2005-09-06 2009-05-12 Biogreen As brotos de linho desmucilados e seu subproduto bem como produção e aplicação dos mesmos
FR2906719A1 (fr) * 2006-10-05 2008-04-11 Limousine D Applic Biolog Dite Utilisation de substances agissant sur le derme papillaire pour leur action anti-age.
EP2190303A1 (fr) * 2007-09-12 2010-06-02 Københavns Universitet Compositions et procédés pour mieux supprimer la sensation de faim et réduire la digestibilité d'une énergie non grasse et prolonger l'effet de satiété
IT1391658B1 (it) * 2008-11-10 2012-01-17 Aboca Spa Societa Agricola Estratti di piante medicinali ottenibili per rimozione o neutralizzazione della frazione farmacologicamente attiva e composizioni che li contengono
FR3004936B1 (fr) * 2013-04-24 2016-02-05 Univ Reims Champagne Ardenne Procede d'obtention d'un melange d'oligosaccharides neutres extraits de graines de lin.
KR101440844B1 (ko) * 2013-05-13 2014-09-17 주식회사 코씨드바이오팜 아마씨 점액 또는 점액 추출물을 함유하는 화장료 조성물
NO338131B1 (no) 2014-06-17 2016-08-01 Trikag As Anvendelse av vandig uttrekk fra brune/sorte linfrø i lyst glutenfritt bakverk
CN110357808A (zh) * 2019-06-13 2019-10-22 上海上药新亚药业有限公司 一种盐酸洛哌丁胺的结晶工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE468600A (fr) *
FR899129A (fr) * 1943-06-25 1945-05-22 Perfectionnements à la fabrication des savons à barbe et nouveaux produits en résultant
FR3848M (fr) * 1964-05-04 1966-01-17 Robert Schapiro Associations thérapeutiques pour traitement de nombreux troubles digestifs organiques ou fonctionnels.
US3338304A (en) * 1965-08-30 1967-08-29 Pan American Petroleum Corp Waterflooding process using mucilage gum thickeners
FR2157676A2 (en) * 1971-09-27 1973-06-08 Delors Jean Claude Stabilising aq emulsions of fatty materials - by addn of mucilaginous plants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9316707A1 *

Also Published As

Publication number Publication date
AU3509493A (en) 1993-09-13
WO1993016707A1 (fr) 1993-09-02
JPH07504182A (ja) 1995-05-11
GB9203474D0 (en) 1992-04-08
CA2130350A1 (fr) 1993-09-02

Similar Documents

Publication Publication Date Title
EP0674522A1 (fr) Mucilage de graines de lin
Singla et al. Chitosan: Some pharmaceutical and biological aspects‐an update
Andrews et al. Mucoadhesive polymeric platforms for controlled drug delivery
AU645791B2 (en) Sustained release of active agents from bioadhesive microcapsules
JPS62215349A (ja) 封入された活性成分を含有する食品及びその調整方法
JPH05503285A (ja) グルカン配達系及び補薬
WO2004045537A2 (fr) Film comestible servant au soulagement de la toux ou de symptomes associes a la pharyngite
EP1462095A1 (fr) Procédé et dispositif pour minimiser les dommages provoqués par la chaleur, humidité ou cisaillement aux principes actifs et autres compositions
WO1995011665A1 (fr) Forme galenique a administration orale pour animaux, son procede de preparation et ses applications
WO2013173697A1 (fr) Pellicules minces à dissolution orale contenant des allergènes et leurs procédés de réalisation et d'utilisation
US20040131662A1 (en) Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
Hasnain et al. Pharmaceutical applications of locust bean gum
TW200418510A (en) Enzyme enhanced breath freshening film
DE60121771T2 (de) Verwendung von alginaten zur hemmung des pepsins
Momoh et al. In vitro study of release of metronidazole tablets prepared from okra gum, gelatin gum and their admixture
KR102224224B1 (ko) 식용 가능한 시트형 물품
FR2710649A1 (fr) Film polymérique à base de prolamines, son procédé de préparation et ses applications .
Arulanandraj et al. NANOTECHNOLOGICAL APPROACH TO ENHANCE THE STABILITY AND BIOAVAILABILITY OF THE HERBAL DRUG" MURVA"
Mohan et al. An review on natural polymers approaches to floating drug delivery system
JP2000256182A (ja) 抗菌製剤
Kadam et al. Role of natural polymer in sustained and controlled release
EP4312996A1 (fr) Procédés d'extraction de microcapsules dispersibles (immunocontraception)
Takeda et al. Influence of pectins on preparation characteristics of lactoferrin bioadhesive tablets
SAQUIBHASNAIN et al. Pharmaceutical Applications of Locust Bean Gum
Augustine et al. Polyuronates and their application in drug delivery and cosmetics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19950913

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970130